1) Santoro A, Viviani S, Villarreal CJR, et al: Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 70: 343-348, 1986.
2) Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-1488, 1992.
3) Rosenberg SA: The low-grade non-Hodgkin's lymphomas: Challenges and opportunities. J Clin Oncol 3: 299-310, 1985.
4) Tobinai K, Kobayasi Y, Narabayashi M, et al: Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol 9: 527-534, 1998.
5) Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993.